Meet Some of the Physicians
and Cervical Spinal Cord
Injury Patients in the
AST-OPC1 Clinical Trial

Clinical Trials

Click here to
learn more.

SciStar Study - Asterias Bio
The SCiStar study has completed enrollment.
The participants who have received AST-OPC1 will continue to be followed and Asterias Biotherapeutics will provide periodic study results updates at this website.


Stock Quote
Asterias Biotherapeutics, Inc. is a biotechnology company pioneering the field of regenerative medicine. The company's proprietary cell therapy programs are based on its immunotherapy and pluripotent stem cell platform technologies. Asterias is presently focused on advancing three clinical-stage programs which have the potential to address areas of very high unmet medical need in the fields of neurology and oncology. AST-OPC1 (oligodendrocyte progenitor cells) is currently in a Phase 1/2a dose escalation clinical trial in spinal cord injury.

Asterias Biotherapeutics Tel: (510) 456-3800